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Abstract
Purpose Gastrointestinal mucositis, commonly associ-
ated with diarrhea, is a dose-limiting toxicity of chemo-
therapy. The new benzamidine derivative CR3294 reduces
tissue damage in animal models of intestinal inﬂammation.
Thus, we tested whether CR3294 had the potential to
prevent chemotherapy-induced mucositis.
Methods In tests on isolated cells, reactive oxygen spe-
cies (ROS) formation and cytokine release were measured
by chemiluminescence and immunoassays, respectively. In
studies in vivo, BDF1 mice were given oral CR3294 (2.5–
20 mg/kg) for 3 days before receiving 5-ﬂuorouracil.
Intestinal crypt survival, cell apoptosis and proliferation,
and diarrhea score were assessed. Additionally, nude mice
bearing tumor xenografts were treated with CR3294 and/or
5-ﬂuorouracil, and tumor growth was monitored.
Results CR3294 signiﬁcantly inhibited cytokine release
from stimulated leukocytes at concentrations similar to the
IC50 (2.9 ± 0.2 lM) for ROS production by these cells.
Consistent with these molecular ﬁndings, CR3294 dose-
dependently protected the intestinal mucosa against 5-ﬂuoro-
uracil-induced toxicity in a mouse model of mucositis. The
numberofsurvivingcryptspercross-sectioninmicereceiving
20 mg/kgCR3294was2.8-foldthatinvehicle-treatedanimals
(18.1 ± 1.9 vs. 6.5 ± 0.9, P\0.001). Moreover, CR3294
decreased the cumulative diarrhea score by 50%, reduced by
nearly 70% the incidence of severe episodes, andincreased by
3-fold the number of mice without diarrhea. CR3294 neither
affected the growth of tumor xenografts nor protected tumors
from the cytotoxic activity of 5-ﬂuorouracil.
Conclusions This study demonstrates that CR3294 acts
on key molecular targets to reduce the signs of mucositis
and the occurrence of diarrhea in mice exposed to the
chemotherapy drug 5-ﬂuorouracil.
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Introduction
Chemotherapy and radiation therapy are useful for treating
many forms of cancer. However, they also affect rapidly
dividing cells in healthy tissues, in particular the epithelial
cells of the alimentary tract. This is the reason why oral and
gastrointestinal(GI)mucositiscommonlyarisesasanadverse
effect of anticancer therapy and often causes dose delays or
reductions, which can hamper treatment success [1–3].
GI mucositis is associated with many chemotherapy
protocols and with radiotherapy directed to any part of the
GI tract. These treatments kill progenitor cells in the crypts
of Lieberku ¨hn, at the base of the villi, with consequent
breakdown of the mucosal barrier [1]. Diarrhea is one of
the most common manifestations of GI mucositis. The
incidence and severity of diarrhea vary greatly, depending
on the therapeutic regimen chosen. Chemotherapy-induced
diarrhea (CID) occurs in as many as 80% of patients with
cancer treated with 5-ﬂuorouracil (5-FU) and irinotecan. Of
even greater concern, increased death rates from GI
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plus bolus 5-FU/leucovorin [3–7]. As the impact of CID
rises with the advent of more aggressive anticancer thera-
pies, new therapeutic options for preventing GI mucositis
and diarrhea are awaited [5, 6, 8, 9].
CR3294 belongs to a novel series of anti-inﬂammatory
agents that inhibit the expression of inducible nitric oxide
synthase (iNOS). Notably, this compound protects the epi-
thelium from injury in validated animal models of GI
inﬂammation [10, 11]. Mucositis is now regarded as a
complex phenomenon in which many cellular and tissue
components of the mucosa play a part. In essence, reactive
oxygen species (ROS) activate downstream signaling path-
ways, transcription factors mediate the expression of target
genes such as interleukin (IL)-1b, IL-6, and tumor necrosis
factor-a (TNF-a), and these cytokines fuel a vicious loop
that harms mucosal integrity [12–15]. On the basis of the
evidence available and because of the unmet medical need,
CR3294 was tested as a preventive agent against mucositis.
The aims of this study were to provide in vitro data that
support a role for CR3294 in reducing the molecular triggers
formucositisandtoassess,inarelevantanimalmodel,whether
CR3294hasthepotentialtopreventGImucositisanddiarrhea.
Materials and methods
Materials
CR3294, N-[4-[[(pentylamino)thioxomethyl]amino]phenyl]-
ethanimidamide,monohydrochloride,wassynthesizedbythe
Medicinal Chemistry Department of Rottapharm S.p.A.
(Monza, Italy). Phorbol-12-myristate-13-acetate (PMA),
luminol,HISTOPAQUE-1077,andlipopolysaccharide(LPS)
were from Sigma (Milan, Italy); dextran T500 was from
Amersham Pharmacia Biotech (Uppsala, Sweden); and
multiplex human cytokine kits were from Bio-Rad (Milan,
Italy). All general purpose reagents used in animal studies
were from Sigma–Aldrich (Poole, UK). Animals were pur-
chasedfromHarlanLaboratoriesUKLtd.,andtumorcelllines
were from the American Type Culture Collection (ATCC).
Wepurchased5-FUfromRoche(WelwynGardenCity,UK).
Rat anti-5-bromo-20-deoxy-uridine (BrdU) clone U1/75
(ICR1)antibodywasfromAbDSeroTecMorphoSysUKLtd.,
with labeling detected using the ABC Elite system from
Vector Laboratories UK Ltd.
In vitro studies
ROS production by human polymorphonuclear leukocytes
(neutrophils)
Venous blood was collected from healthy human donors in
sodium citrate 0.38% and centrifuged at 275g for 15 min.
The resulting buffy coat was diluted 3 times (3–9 mL) with
phosphate-buffered saline (PBS) and mixed with 2 mL of
6% dextran T500 in 0.9% saline. This mixture was left for
45 min at room temperature, then the supernatant was
collected and centrifuged at 275g for 15 min. The pellet
(leukocytes) was subjected to hypotonic lysis of contami-
nating erythrocytes by addition of distilled water. The
osmolarity was restored with 0.8% NaCl solution. Leuko-
cytes were then centrifuged at 275g for 15 min and washed
again in PBS. Polymorphonuclear leukocytes (PMNL)
were isolated by gradient centrifugation (400g for 30 min)
on HISTOPAQUE-1077. Puriﬁed PMNL were suspended
in PBS plus 0.87 mM CaCl2 and 1 mM MgCl2, counted,
and diluted to 2.5 9 10
6 cells/mL. For chemiluminescence
assays, the PMNL suspension was premixed with luminol
(5 lM ﬁnal). Aliquots of cell suspension (200 lL) were
incubated with CR3294 (1, 3, or 10 lM) or its vehicle
(distilled water) for 10 min at 37C. Next, PMNL were
activated with 0.1 lM PMA, and light emission was
monitored at 3-min intervals for 24 min in a HTS7000 plus
microplate reader. Results are expressed as relative lumi-
nescence units (RLU).
Cytokine release from peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMC) were isolated
by density gradient centrifugation on HISTOPAQUE-1077,
according to the manufacturer’s instructions. Puriﬁed cells
wereresuspendedinRPMI-1640culturemediumcontaining
1% fetal bovine serum and adjusted to 2 9 10
6 cells/mL.
Aliquots of cell suspension (200 lL) were added to dupli-
cate wells of a ﬂat-bottom 96-well plate containing CR3294
orvehicle(distilledwater) andincubatedfor1 hat37Cina
humidiﬁed atmosphere of 5% CO2. Cytokine synthesis was
induced by a 4-h stimulation with 1 lg/mL LPS (from
E. coli, serotype 0127B7). To rule out cytotoxic effects,
parallel plates were tested for viability by MTT [3-(4,
5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
assay.Attheendoftheincubationperiod,supernatantswere
collected and assayed for IL-1b, TNF-a, IL-6, and IL-8 by
Bio-Plex technology (BioRad, Milan, Italy) according to the
recommended procedures. Data were analyzed using the
Bio-Plex Manager
TM software from Bio-Rad (version 4.0),
and results are given as IC50 values (lM).
In vivo studies
Ethics and animal care
All studies were conducted in accordance with the UK
Home Ofﬁce Animals (Scientiﬁc Procedures) Act 1986, at
standards equivalent to the UKCCCR guidelines for the
welfare of animals in experimental neoplasia [16]. Animals
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123were held in individually ventilated cages in a speciﬁc
pathogen-free barrier unit. On arrival from the supplier,
mice were housed for 2 weeks to enable acclimatization
and stabilize the circadian rhythm. Mice were identiﬁed by
numbered cages and by ear punches. There was a constant
room temperature of 21 ± 2C and a mean relative
humidity of 55 ± 10%. The day–night cycle was constant,
with light and dark phases of 12 h each. Both feed and
water (from drinking bottles) were available ad libitum.
Animal health was monitored daily and cages were cleaned
at regular intervals.
Analysis of intestinal crypt survival
Male BDF1 mice (10–12 weeks of age, n = 8 per group)
were used in this experiment. CR3294 was stored at room
temperature in the dark: solutions were prepared fresh each
day in deionized water, and concentrations were adjusted to
give the appropriate dose (2.5, 5, 10, or 20 mg/kg) in
100 lL. Intestinal damage was induced by either 5-FU
(2 9 450 mg/kg intraperitoneally, 6 h apart) or irradiation
(13 Gy) on day 0 of the study, after 3 days of once-daily
oral administration of CR3294 or its vehicle. Irradiation
was administered by a Pantak HF320 X-ray unit (Agfa
NDT Ltd., Reading, UK). The machine was operated at
300 kV, 10 mA. The X-ray tube was ﬁtted with additional
ﬁltration to give a radiation quality of 2.3-mm Cu half-
value layer (HVL). Mice were restrained in a jig positioned
at a distance of 700 mm from the focus of the X-ray tube,
and irradiation was delivered at a dose rate of 70 cGy/min.
An examination of body weight, general condition,
behavior, and mortality was performed daily for each
mouse. Animals were killed 4 days after the last dose of
the cytotoxic insult. The small intestine was removed, ﬁxed
in Carnoy’s ﬁxative, parafﬁn embedded, and processed for
histology with hematoxylin and eosin (H&E) stain. Ten
intestinal circumferences per mice were analyzed. The
number of surviving crypts per circumference was scored
and the group mean was determined [17, 18]. Only crypts
containing 10 or more strongly H&E-stained cells
(excluding Paneth cells), only intact circumferences not
containing Peyer’s patches, were scored. The mean crypt
width (at its widest point) was also measured to correct for
scoring errors due to crypt size differences [19]. The fol-
lowing correction was applied:
Corrected number of crypts per circumference ¼
ðmean crypt width in untreated controls=mean
crypt width in treatment groupÞ
  mean number of surviving crypts in treatment group:
The effects of CR3294 were also expressed as
Protection Index, i.e., the ratio of surviving crypts in
treatment group to surviving crypts in vehicle control
group.
Cell proliferation and apoptosis
Male BDF1 mice (10–12 weeks of age, n = 6 per group)
were randomized into 7 groups and divided into 2 experi-
ments. In the ﬁrst one, we tested the effect of CR3294
(20 mg/kg) on crypt cell proliferation 24 h after 3 daily
doses (i.e., the time at which 5-FU is administered). Ani-
mals were dosed with 10 mg of BrdU (0.5 mL intraperi-
toneally) 40 min before killing. In the second experiment,
we examined the levels of apoptosis 4.5 h after exposure to
single or repeated (2 times, 6 h apart) cytotoxic doses of
5-FU (450 mg/kg). Mice were killed by cervical disloca-
tion in both studies. The small intestine was removed, ﬁxed
in Carnoy’s ﬁxative, parafﬁn embedded, and sectioned to
generate 2 non-serial sections per slide. Carnoy’s ﬁxed
sections were either labeled to reveal BrdU incorporation
or H&E stained to measure the incidence of apoptosis.
Crypts were analyzed on a cell positional basis to identify
drug-induced changes. In all cases, 50 half-crypts per
mouse were scored—300 scores per group, from which the
frequencies were generated [20]. Quantiﬁcation of BrdU
labeling and apoptosis was performed by the purpose-built
WinCrypts software program, which analyzes the statistical
signiﬁcance of any distributions using an extension of the
median test. At each cell position, the common median for
all the animals was calculated, and then the individual
values for each animal were classiﬁed as being below or
above the median [21].
Diarrhea assessment
Male BDF1 mice (10–12 weeks of age, n = 15 per group)
were randomized into 2 groups. Dosage regimens for 5-FU
and CR3294 (20 mg/kg) were consistent with those used in
the experiments described earlier. Mice were weighed
once-daily after the beginning of treatment. Similarly,
animal well-being was checked daily, and the incidence
and severity of diarrhea were scored. Checks increased to
twice a day during days 4–11. Scores were recorded as 0, 1,
2, or 3 where 0 is normal stool consistency, 1 is loose
stools, 2 is overt diarrhea, and 3 is liquid feces with severe
perianal/tail soilage (extreme diarrhea). Surviving animals
were to be killed 20 days after the cytotoxic insult.
Tumor proliferation models
Two experiments were carried out to rule out adverse
effects of CR3294 on tumor growth or 5-FU activity. In the
ﬁrst study, 16 male and 16 female BALB/c nude mice were
xenografted with human colorectal (HT29) and breast
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123(MDA-MB-231) cancer cells, respectively. Tumors were
measured with calipers 3 times per week and were allowed
to grow until the mean tumor volume of the group reached
100–150 mm
3. Animals were treated with 20 mg/kg
CR3294 or vehicle (sterile water) daily for 14 days. In the
second study, 32 male BALB/c nude mice were xeno-
grafted with the colorectal HT29 cell line and randomized
into 4 treatment groups. Groups 2 and 4 were treated with
oral CR3294 on days 1–3 and 8–10 (incorporating a 5-day
interval). The cytotoxic treatment (5-FU, 25 mg/kg intra-
peritoneally) was administered on days 1–5 in group 4 as
well as in cytotoxic control group 3. The dual vehicle
control group (group 1) was administered with the test
agent vehicle (water) on days 1–3 and 8–10 and with the 5-
FU vehicle (saline) on days 1–5. All the mice in both
studies were weighed 3 times per week. Well-being was
checked daily: any animal with more than 15% weight loss
was considered unwell and killed if the weight loss was
greater than 20%. If an animal became unwell, any treat-
ment of that animal was suspended. If there was no
recovery, the mouse was killed. Tumor sizes were mea-
sured for up to 28 days after the ﬁrst dose of CR3294 or
vehicle.
Statistics
For the evaluation of statistical differences between exper-
imental groups, one- or two-way analysis of variance
(ANOVA) followed by Holm–Sidak test for multiple com-
parisons were used. Data without homogeneity of variance
were analyzed with Mann–Whitney rank sum test or Krus-
kal–Wallis one-way ANOVA, and multiple post hoc com-
parisons were performed using Dunn’smethod. In studies of
proliferation and apoptosis, the common median for all the
animals (at each cell position in the crypt) was calculated.
Next,theindividualvaluesforeachanimalwereclassiﬁedas
being below or above the median, and the chi-squared test
was applied on the tabulated frequencies. All analyses were
done with the SigmaStat version 3.5 software, and a sig-
niﬁcance level of 0.05 was used throughout.
Results
In vitro studies
First, we tested the hypothesis that CR3294 has the ability to
inhibitkeymoleculareventsintheonsetofmucositis.Inthese
in vitro studies, we used human PMNL and PBMC because
leukocytes are a rich source of both ROS and cytokines.
Phorbol-12-myristate-13-acetate (PMA) rapidly increased
ROS production by PMNL, as measured by chemilumines-
cence. CR3294 inhibited this response in a concentration
dependentmanner,withanIC50valueof2.9 ± 0.2 lMan da
maximal inhibition of about 76% at 10 lM. The effects of
treatment and time, and their interaction, were all signiﬁcant
(P\0.01, two-way ANOVA). Post hoc analysis showed
signiﬁcant differences across all groups from 6 min onward
(Fig. 1).
To assess the impact of CR3294 on cytokine release,
human PBMC were stimulated with 1 lg/mL LPS for 4 h.
Under these conditions, CR3294 concentration-depen-
dently inhibited the release of TNF-a, IL-6, and IL-8. The
IC50 values ranged between 6 and 9 lM. Moreover,
CR3294 potently inhibited the release IL-1b, with an IC50
of about 100 nM. Similar results were obtained in two
independent experiments, each done in duplicate, and
signiﬁcant inhibitions were generally seen at concentra-
tions of 3 lM or higher.
In vivo studies
Effects of CR3294 on the mucosal epithelium
Next, we studied whether orally administered CR3294
could protect crypt cells in the intestinal mucosa against
damage induced by chemotherapy or radiation. We tested
PMA
+   1 µM CR3294
+   3 µM CR3294
+ 10 µM CR3294
Time (minutes)
R
L
U
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1000
1500
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2500
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3500
01 0 2 0 3 0
Fig. 1 Effects of increasing concentrations of CR3294 on ROS
production by PMNL stimulated with PMA. Between-group differ-
ences are all P\0.05 from 6 min onward (Holm–Sidak method).
Similar results were obtained in 3 independent experiments per-
formed in quadruplicate. ROS reactive oxygen species, PMNL
polymorphonuclear leukocytes, PMA phorbol-12-myristate-13-acet-
ate, RLU relative luminescence units
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123different dosing schemes and found that CR3294 was
especially effective when given as a preventive measure—
i.e., 72, 48, and 24 h before cytotoxic treatment. Under
these conditions, none of the animals receiving 5-FU died
before the scheduled killing time (4 days after the last dose
of 5-FU). All mice, except those in the untreated control
group, lost weight to similar extents and with similar
kinetics (not shown). CR3294 protected the mucosa against
5-FU-induced toxicity, and there was a clear dose–response
effect. The corrected number of surviving crypts per cir-
cumference in the group treated with 20 mg/kg CR3294
was nearly 3-fold that in vehicle-treated mice (18.1 ± 1.9
vs. 6.5 ± 0.9, Protection Index 2.8, P\0.001; Table 1).
Conversely, no conclusive effects of CR3294 were seen in
a model of radiation-induced mucositis. The Protection
Index ranged from 1 to 1.9 in three different experiments,
and there was no clear dose–response relationship.
More experiments were run to determine whether
CR3294 protected the epithelium by increasing cell
proliferation or by decreasing the sensitivity of crypt
cells—either all cells or a particular cell type in the crypt
hierarchy—to 5-FU-induced apoptosis. As expected,
sections of small intestine from control mice showed
high levels of proliferation: about half of the cells in the
mid-crypt region were labeled with BrdU. Twenty-four
hours after the last dose of CR3294 (20 mg/kg), there
were no signiﬁcant changes in the frequency or distri-
bution of BrdU labeling (Fig. 2a). One or two doses (6 h
apart) of 5-FU induced progressively higher rates of crypt
cell apoptosis. Pretreatment with 20 mg/kg of CR3294
did not affect the levels of apoptosis induced by 5-FU
(Fig. 2b).
Effect of CR3294 on 5-FU-induced diarrhea
We then assessed in a proof-of-concept study whether
CR3294, at the dose (20 mg/kg) that signiﬁcantly
decreased mucosal damage, also reduced the incidence
and/or severity of diarrhea in mice exposed to 5-FU. Nearly
all mice (13 out of 15) receiving 5-FU and vehicle devel-
oped diarrhea starting from day 4. The number of mice
without diarrhea for the entire study was 3-fold higher in
the group treated with CR3294 than in vehicle-treated
animals. Moreover, pretreatment with CR3294 reduced the
cumulative symptom score by 50% (Fig. 3). Moderate-to-
severe diarrhea (grade 2–3) was more frequent in the
vehicle-treated group than in the group treated with
CR3294 (13 vs. 4 observations; nearly 70% reduction).
Similar results were found when we analyzed the 7-day
study period during which all mice were alive (Fig. 4).
Statistical analysis showed a signiﬁcant difference
(P\0.05, Mann–Whitney rank sum test) between the two
groups in the median diarrhea score.
Animals died between days 8 and 13 after 5-FU chal-
lenge. Thus, CR3294 did not improve survival, although
the onset of death was slightly delayed in the group
receiving the active treatment (4 deaths during days 8 and 9
vs. 7 deaths during the same period in the vehicle-treated
group).
Tumor proliferation models
To rule out adverse effects of CR3294 on tumor growth
or 5-FU activity, we ﬁnally undertook two studies in
xenograft models of human colorectal (HT29)/breast
(MDA-MB-231) cancer. In the ﬁrst study, the mean
volume of HT29 and MDA-MB-231 tumors grew about
10- and 7-fold, respectively, over 1 month. Two weeks
of treatment with CR3294 20 mg/kg once-daily had no
effect on the rate of tumor growth (Fig. 5a, b) and did
not affect animal weight. In the second study, 5-FU
inhibited the growth of HT29 xenografts, and CR3294
did not hamper the response to the chemotherapy drug
(Fig. 6).
Table 1 Effect of pretreatment with CR3294 on 5-FU-induced intestinal crypt death
Pretreatment
a Surviving crypts per
circumference
b, mean ± SE
Protection Index, fold change
compared to vehicle-treated controls
Vehicle 6.5 ± 0.9 –
CR3294 2.5 mg/kg 9.9 ± 1.0 1.5
CR3294 5 mg/kg 11.7 ± 2.5 1.8
CR3294 10 mg/kg 11.8 ± 1.2 1.8
CR3294 20 mg/kg 18.1 ± 1.9* 2.8
Each treatment group comprised 8 mice
a 72, 48, and 24 h before 2 9 450 mg/kg 5-FU
b Corrected number, expressed as the following ratio: (mean crypt width in untreated controls/mean crypt width in treatment group) 9 mean
number of surviving crypts in treatment group
* P\0.001, Holm–Sidak method
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123Discussion
Severe alimentary mucositis has a major impact on patients
undergoing chemotherapy or radiation therapy. There is
clearly an unmet medical need for drugs that reduce the
rate and severity of GI mucositis and diarrhea [9]. Indeed,
clinical practice guidelines call for sustained efforts to
develop better therapeutic strategies, targeted to the
mechanisms of mucosal injury [22]. The present experi-
mental study demonstrates that CR3294 improves the signs
and symptoms of GI mucositis by blocking key molecular
events in the pathogenesis of this condition.
CR3294 is an anti-inﬂammatory agent that inhibits the
expression of iNOS and cyclooxygenase 2 (COX-2) [10].
Recent ﬁndings suggest a role for iNOS and COX-2 in the
onset of mucositis [12, 14, 23]. However, it is widely
accepted that ROS initiate the cascade of events—includ-
ing increased levels of inﬂammatory cytokines—that leads
to mucosal damage [12]. In this study, CR3294 inhibited
the release of IL-1b, IL-6, IL-8, and TNF-a from stimu-
lated leukocytes at concentrations similar to those required
to inhibit ROS production by these cells. The link between
oxidative stress and mucositis is conﬁrmed by other studies
in which ROS scavengers were tested as protective agents
against radiation-induced damage [24, 25]. Palifermin, the
only drug approved for the treatment of oral mucositis, is a
human keratinocyte growth factor (KGF) produced by
recombinant DNA technology. In addition to stimulating
epithelial cell proliferation, KGF activates the transcription
factor NF-E2-related factor 2 (Nrf2), which in turn
increases the expression of ROS-scavenging enzymes [26].
Because the use of anti-inﬂammatory agents is now
regarded as a promising approach to reduce the severity of
mucositis [27], there is a strong rationale for developing
new drugs with combined ROS-scavenging and anti-
inﬂammatory properties. This is particularly relevant to GI
mucositis, for which no therapy is currently approved
although a variety of agents have been assessed in
preclinical and clinical studies. Recently, alternative med-
icine approach gained attention. Probiotics have been
shown to reduce intestinal inﬂammation and diarrhea in
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123experimental models of GI mucositis in rats [28–30].
Herbal extracts, due to their anti-inﬂammatory and anti-
oxidative properties and in keeping with CR3294 activity,
have been shown to decrease mucosal damage in preclin-
ical and clinical studies [31, 32].
The main goal of this study was to examine whether
CR3294 has the potential to prevent GI mucositis and
diarrhea. In a ﬁrst set of in vivo experiments, we found that
CR3294 signiﬁcantly protected crypt cells against damage
induced by 5-FU. Conversely, no deﬁnite effects were seen
in an experimental model of radiation-induced mucositis.
Different factors could account for the lack of conclusive
results in this experimental setting. First, the adopted pro-
tocol may be non-optimal. Further studies with different
radiation schemes have been planned to test the above
hypothesis. Additionally, because X-rays and 5-FU target
different cells in the intestinal crypts [33], it is conceivable
that CR3294 protects a speciﬁc cell type in the crypt hier-
archy. Unlike KGF, CR3294did not stimulateepithelial cell
proliferation, but similarly to KGF, the effectiveness of
CR3294 was greatest when it was administered in a pre-
ventive mode [34]. This ﬁnding suggests that other mecha-
nisms, besides ROS scavenging, contribute to the
cytoprotective activity of this agent. One such mechanism
may involve decreased sensitivity to 5-FU-induced apop-
tosis [35], but our experiments did not show signiﬁcant
differences in this regard. Alternatively, given that CR3294
can induce the formation of autophagosomes [10], it is
possible that CR3294 increased crypt survival by activating
the autophagic pathway. Autophagy may indeed serve as a
rescue mechanism whereby cells extend their lifespan under
critical conditions [36]. Although analyzing autophagy-
related processes was beyond the scope of our present work,
studies are under way to test the above hypothesis.
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Fig. 5 Tumor growth curves in control and CR3294-treated groups. a
Male BALB/c nude mice (n = 8 per group) were xenografted with
human colorectal (HT29) cancer cells and treated with vehicle (sterile
water) or CR3294 for 14 days. b Female mice (n = 8 per group) were
xenografted with human breast (MDA-MB-231) cancer cells and
treated with CR3294 or its vehicle for 14 days
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123Here, we were interested in assessing whether mucosal
protection could translate into a lower incidence of diar-
rhea, because CID is associated with dose reductions, dose
delays, and excess hospitalizations and deaths. In our
proof-of-concept study, pretreatment with CR3294 halved
the cumulative diarrhea score in mice exposed to 5-FU.
CR3294 was particularly effective against moderate-to-
severe CID: animals treated with the 20 mg/kg dose were
70% less likely to experience grade 2–3 diarrhea than
vehicle-treated mice. Severe diarrhea is common in
patients receiving ﬂuoropyrimidine-based chemotherapy
[4, 6, 37]. In the absence of effective drugs to avoid this
adverse event, treatment has superseded prevention in the
clinical setting, and high-dose loperamide is used for
managing mild-to-moderate diarrhea. Unfortunately, lop-
eramide is far less effective when it comes to severe epi-
sodes, those that may be life threatening [7, 37, 38].
CR3294 did not improve animal survival, even though it
slightly delayed the onset of death after exposure to 5-FU.
However, our proof-of-concept study was designed to
detect an effect of the compound on diarrhea rate and
severity rather than on death from GI syndrome. Damage to
the GI tract, if sufﬁciently serious, would cause death
within 6–7 days, whereas none of the mice in our study
died before day 8 after 5-FU injection. So, mortality was
presumably associated with damage to the hematopoietic
system [39]; and clearly, CR3294 did not limit chemical-
induced toxicity to the bone marrow.
Likewise, CR3294 neither altered the antitumor activity
of 5-FU nor affected the growth rate of tumor xenografts in
both female and male mice. Candidate drugs for the pre-
vention or treatment of mucositis must not protect tumors.
For instance, other authors have demonstrated that palif-
ermin does not stimulate the growth of tumors, even those
expressing the KGF receptor [29, 40]. Regardless that
CR3294 is unlikely to promote cell proliferation via KGF-
dependent mechanisms, we ruled out unexpected yet pos-
sible untoward effects. A recent study has even shown that
CR3294 reduces tumor growth in vivo [10]. The variable
results between that study and the present one might be due
either to the different models used or to the different
duration of treatment (8 vs. 2 weeks).
In summary, our experimental study demonstrates that
CR3294 acts on critical mechanisms of mucosal injury to
reduce the signs of GI mucositis as well as the incidence
and severity of 5-FU-induced diarrhea. These positive
results warrant further investigation in humans because no
drugs are currently approved for the prevention of CID.
Phase I clinical trials are now under way to evaluate the
safety proﬁle of CR3294.
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